Skip to main content
SpringerLink
Log in

Atezolizumab/nivolumab/pembrolizumab

Immune-mediated encephalitis and immune-mediated encephalopathy

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Fonseca E, et al. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study. [Review] Lancet Neurology 22 : 1150-1159, No. 12, Dec 2023. Available from: URL: https://dx.doi.org/10.1016/S1474-4422(23)00335-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atezolizumab/nivolumab/pembrolizumab. Reactions Weekly 1996, 36 (2024). https://doi.org/10.1007/s40278-024-53489-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-024-53489-1

Search

Navigation